Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
Pneumologie · 01.03.2023 · 77 (S 01 S 01) · S57
DOI: 10.1055/s-0043-1761002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pneumologie, erschienen am 01.03.2023. Verfasst von F Bonella und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Rationale
Elderly ILD patients are more likely to be frail and to have comorbidities that complicate their care. We investigated the efficacy and safety of nintedanib in elderly patients with progressive fibrosing (PF-) ILDs other than idiopathic pulmonary fibrosis (IPF) in the INBUILD trial ([ Abb. 1 ]). Abb. 1 Rate of decline in FVC (m/year) over 52 weeks in the INBUILD trial in subgroups by age at baseline.
Methods
Patients had a chronic fibrosing ILD other than IPF, reticular abnormality with traction bronchiectasis (with/without honeycombing) of>10% on HRCT, and met criteria for ILD progression within the 24 months before screening, despite management deemed appropriate in clinical practice. Patients were randomized to nintedanib or placebo. We analyzed the rate of decline in FVC (mL/year) over 52 weeks in subgroups by age
Zitieren
APA
Bonella, F., Moua, T., Okamoto, M., Tomassetti, S., Valenzuela, C., Wuyts, W., Miede, C., Lievens, D., & Bendstrup, E. (2023). Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*. Pneumologie, 77(S 01 S 01), S57. https://doi.org/10.1055/s-0043-1761002
Vancouver
Bonella F, Moua T, Okamoto M, Tomassetti S, Valenzuela C, Wuyts W, et al. Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*. Pneumologie. 2023;77(S 01 S 01):S57. doi:10.1055/s-0043-1761002
BibTeX
@article{Bonella2023,
author = {Bonella, F and Moua, T and Okamoto, M and Tomassetti, S and Valenzuela, C and Wuyts, W and Miede, C and Lievens, D and Bendstrup, E},
title = {Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*},
journal = {Pneumologie},
year = {2023},
volume = {77},
number = {S 01 S 01},
pages = {S57},
doi = {10.1055/s-0043-1761002}
}
EUVIMED